• Explore /
  • Poster
  • / TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer.

TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer.

Abstract Poster

Authors

null

Daisuke Kotani

National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan;

Daisuke Kotani , Yoshinori Kagawa , Yuki Matsubara , Hideaki Bando , Kazuaki Harada , Naoki Takahashi , Yoshiaki Mihara , Izuma Nakayama , Naoki Izawa , Takeshi Kawakami , Toshiki Masuishi , Hiroko Hasegawa , Takashi Ohta , Masashi Wakabayashi , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

031210511

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS264)

DOI

10.1200/JCO.2023.41.4_suppl.TPS264

Abstract #

TPS264

Poster Bd #

P6

Abstract Disclosures

Similar Posters

First Author: Yuki Matsubara

Poster

2018 Gastrointestinal Cancers Symposium

BEACON CRC study safety lead-in (SLI) in patients with <em>BRAF</em><sup>V600E</sup> metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

First Author: Eric Van Cutsem

First Author: Sanne Huijberts

Poster

2023 ASCO Gastrointestinal Cancers Symposium

BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for <em>BRAF</em><sup>V600E</sup> metastatic colorectal cancer (mCRC).

BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).

First Author: Scott Kopetz